Navigation Links
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
Date:8/22/2008

OGX-011 treatment can significantly reduce serum clusterin levels and that achieving low serum clusterin levels during treatment is correlated with improved survival. Furthermore, serum clusterin levels during OGX-011 treatment may be predictive of a treatment benefit with OGX-011. In patients with HRPC who had failed first-line docetaxel while on or within six months of first-line docetaxel therapy and received second-line chemotherapy in combination with OGX-011 (Study OGX-011-07), achieving or maintaining low serum clusterin levels correlated with improved survival. Similar results were seen in Study OGX-011-05 in patients with NSCLC who were treated with gemcitabine plus a platinum regimen and OGX-011. Data from the Phase 2 study in HRPC were presented at the 2008 Annual Meeting of the American Society of Clinical Oncology.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of specific proteins associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning Fast Track Designation for OGX-011 and anticipated clinical and other product development activities and
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline To Post Quarterly US Grants Report
2. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
3. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
4. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
5. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
10. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
11. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
(Date:4/30/2015)... April 30, 2015  The Paul G. Allen Family ... (ADI) grants to six groups of researchers with projects ... roadblocks in neuroscience: growing mature human brain cells in ... of $7.5 million over three years.  ... research is especially significant because the field of neuronal ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... provider, today announced that its board of directors has ... 2015, from a consortium (the "Consortium") led by Dr. ... chief executive officer of the Company, and Ally Bridge ... "Transaction") involving the acquisition of all outstanding shares of ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., (Nasdaq: ... ) today announced that the U.S. Food and Drug Administration ... BYETTA is now approved for use as a stand-alone medication ... in adults with type 2 diabetes. Previously, it was approved ...
... Calif., Oct. 30 ThermoGenesis Corp. (Nasdaq: ... and store adult stem cells, announced today it will report ... 2009, on Thursday, November 5, 2009. , ... host a conference call Thursday, November 5, 2009 at 2:00 ...
... , ROCKVILLE, Md., Oct 30 Novavax, Inc. (Nasdaq: ... third quarter financial results in a press release to be ... 2009. The Company will hold an investor conference call to ... Friday, November 6, 2009. The call will be hosted by ...
Cached Biology Technology:BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009 2Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call 2
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... The first real-world, demonstration-scale project in Nevada for ... stage of research at the University of Nevada, Reno. ... is an economical, commercially viable renewable energy source in ... outdoor cold-weather crop of algae as part of their ...
... TGen Clinical Research Services (TCRS) at Scottsdale Healthcare ... may offer broad potential to treat solid tumors. ... conducted at TGen Clinical Research Services at Scottsdale Healthcare, ... (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo ...
... bleaching is not only a con, but is dangerous to ... journal. The light treatment gives absolutely no benefit over ... four times as much as sunbathing, reports a study in ... match Tom Cruise,s glittering pearly-whites would be better off ignoring ...
Cached Biology News:Success for first outdoor, large-scale algae-to-biofuel research project in Nevada 2TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug 2
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... Molecular Probes intensely fluorescent and ... potential for use in a variety ... deliver a strong signal. Unfortunately, protein- ... regions that may cause them to ...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Biology Products: